Haratani et al. [22] discovered occurrences of MG in patients who received PD-1/PD-L1 inhibitors, highlighting the importance of immunological tolerance mechanisms in preventing autoimmunity. The gene discussed is PDCD1; the disease is myasthenia gravis.